EA201990768A1 - Оптимизированные синтетические консенсусные иммуногенные композиции, нацеленные на белок активации фибробластов - Google Patents

Оптимизированные синтетические консенсусные иммуногенные композиции, нацеленные на белок активации фибробластов

Info

Publication number
EA201990768A1
EA201990768A1 EA201990768A EA201990768A EA201990768A1 EA 201990768 A1 EA201990768 A1 EA 201990768A1 EA 201990768 A EA201990768 A EA 201990768A EA 201990768 A EA201990768 A EA 201990768A EA 201990768 A1 EA201990768 A1 EA 201990768A1
Authority
EA
Eurasian Patent Office
Prior art keywords
immunogenic compositions
activation protein
fibroblast activation
synthetic consensus
optimized synthetic
Prior art date
Application number
EA201990768A
Other languages
English (en)
Inventor
Дэвид Уэйнер
Элизабет Дюперре
Original Assignee
Дзе Уистар Инститьют Оф Энэтоми Энд Байолоджи
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Уистар Инститьют Оф Энэтоми Энд Байолоджи, Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания filed Critical Дзе Уистар Инститьют Оф Энэтоми Энд Байолоджи
Publication of EA201990768A1 publication Critical patent/EA201990768A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001158—Proteinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21026—Prolyl oligopeptidase (3.4.21.26), i.e. proline-specific endopeptidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

В данном документе предложена иммуногенная композиция, содержащая синтетический консенсусный антиген FAP. Также в данном документе раскрыт способ лечения или предупреждения опухоль-ассоциированной патологии у субъекта, нуждающегося в этом, с помощью введения субъекту указанной иммуногенной композиции.
EA201990768A 2016-09-21 2017-09-21 Оптимизированные синтетические консенсусные иммуногенные композиции, нацеленные на белок активации фибробластов EA201990768A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662397469P 2016-09-21 2016-09-21
PCT/US2017/052701 WO2018057727A1 (en) 2016-09-21 2017-09-21 Optimized synthetic consensus inmunogenic compositions targeting fibroblast activation protein

Publications (1)

Publication Number Publication Date
EA201990768A1 true EA201990768A1 (ru) 2019-08-30

Family

ID=61690028

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990768A EA201990768A1 (ru) 2016-09-21 2017-09-21 Оптимизированные синтетические консенсусные иммуногенные композиции, нацеленные на белок активации фибробластов

Country Status (10)

Country Link
EP (1) EP3515466A4 (ru)
JP (1) JP2019532935A (ru)
KR (1) KR20190092371A (ru)
CN (1) CN110167576A (ru)
AU (1) AU2017330338A1 (ru)
BR (1) BR112019005513A2 (ru)
CA (1) CA3037682A1 (ru)
EA (1) EA201990768A1 (ru)
MX (1) MX2019003258A (ru)
WO (1) WO2018057727A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3518955A4 (en) * 2016-09-30 2020-10-07 The Wistar Institute Of Anatomy And Biology TERT IMMUNOGENIC COMPOSITIONS AND METHODS OF TREATMENT USING THEM
CN111118063B (zh) * 2019-12-05 2023-04-18 吉林大学 以FAPα和survivin为基础的DNA及其在制备肿瘤疫苗中的应用
CN112402597B (zh) * 2020-11-26 2022-04-01 四川大学 一种fap修饰的类外泌体纳米囊泡肿瘤疫苗

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472375B1 (en) * 1998-04-16 2002-10-29 John Wayne Cancer Institute DNA vaccine and methods for its use
WO2007149518A2 (en) * 2006-06-21 2007-12-27 The Scripps Research Institute Dna composition against tumor stromal antigen fap and methods of use thereof
MX2012002014A (es) * 2009-08-17 2012-06-13 Roche Glycart Ag Inmunoconjugados dirigidos.
US9238679B2 (en) * 2011-02-11 2016-01-19 The Trustees Of The University Of Pennslyvania Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
US10501512B2 (en) * 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
AU2013243951A1 (en) * 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US9402888B2 (en) * 2013-03-14 2016-08-02 The Wistar Institute Of Anatomy And Biology Methods and compositions for treating cancer
EP3518955A4 (en) * 2016-09-30 2020-10-07 The Wistar Institute Of Anatomy And Biology TERT IMMUNOGENIC COMPOSITIONS AND METHODS OF TREATMENT USING THEM

Also Published As

Publication number Publication date
BR112019005513A2 (pt) 2019-06-11
EP3515466A4 (en) 2020-05-27
CA3037682A1 (en) 2018-03-29
AU2017330338A1 (en) 2019-05-02
JP2019532935A (ja) 2019-11-14
MX2019003258A (es) 2019-09-13
KR20190092371A (ko) 2019-08-07
CN110167576A (zh) 2019-08-23
WO2018057727A1 (en) 2018-03-29
EP3515466A1 (en) 2019-07-31

Similar Documents

Publication Publication Date Title
CL2021000458A1 (es) Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr (divisional de solicitud 201602359)
EA201891186A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
EA201892294A1 (ru) Антитела и композиции против tim-3
EA201891083A1 (ru) Составы антител к cd38 для подкожного введения и их применение
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CY1122329T1 (el) Anti-siglec-8 αντισωματα και μeθοδοι χρhσεως αυτων
EA201790413A1 (ru) Антитела против tigit
MX2016012124A (es) Anticuerpos contra glicopeptidos inmunogenicos, composicion que los comprende y usos de estos.
EA201890131A1 (ru) Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
CO2017001023A2 (es) Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas
EA201791884A1 (ru) Химерные антигенные рецепторы против dll3 и способы применения
EA201790273A1 (ru) Флагеллиновые композиции и их применение
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
EA202091130A1 (ru) Лиофилизованный препарат моноклонального антитела к транстиретину
EA201791907A1 (ru) Бивалентная вакцина против вируса свиного гриппа
BR112017009790A2 (pt) anticorpos direcionados ao anti-ang2 e métodos de uso
CO2017001087A2 (es) Anticuerpos anti proteína similar a angiopoyetina 4
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
EA201990768A1 (ru) Оптимизированные синтетические консенсусные иммуногенные композиции, нацеленные на белок активации фибробластов
EA201990978A1 (ru) Антитела против pd-1
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
EA202190504A1 (ru) Способы лечения псориаза
UY36922A (es) Inhibidores de asgr